Bio-Techne President Steven C. Crouse Receives 22,842 RSUs

What Happened
Steven C. Crouse, President — Diagnostic & Spatial Biology at Bio-Techne (TECH), was granted two awards of restricted stock units (RSUs) on 2026-08-17: 8,702 RSUs and 14,140 RSUs, a total of 22,842 RSUs. Both awards are reported as acquisitions (code A) with an acquisition price of $0.00 (typical for equity awards); the reported total cash value for the transaction entries is $0.

Key Details

• Transaction date: 2026-08-17; Form 4 filed 2026-08-19 (appears timely — filed within two business days).
• Amounts: 8,702 RSUs and 14,140 RSUs (total 22,842 RSUs) at $0.00 acquisition price.
• Derivative type: RSUs (reported as derivative awards, not open‑market purchases or sales).
• Shares owned after transaction: not specified in the supplied excerpt.
• Notable filing footnotes: F8 — each RSU represents a contingent right to receive one share of Bio‑Techne common stock; F16 — the 14,140 RSUs vest on 8/17/2029; the filing includes additional footnotes (F1–F15) that describe other vesting schedules and grants for this insider. See the full Form 4 for complete vesting and applicability of each footnote.

Context
RSU grants are compensation awards and do not represent an immediate market purchase or sale. They convert to actual shares only as they vest per the schedules in the filing; awards reported at $0 are common for RSUs (the economic value is realized when/if RSUs vest and shares are issued). This report does not indicate any immediate sale of the shares.